Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees its stock surge to a 7-year high amid optimism about its strategy and pipeline momentum.
Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees its stock surge to a 7-year high amid optimism about its strategy and pipeline momentum.